Dimension Therapeutics (DMTX) Given Daily News Sentiment Rating of 0.16

Media coverage about Dimension Therapeutics (NASDAQ:DMTX) has trended somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dimension Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.1921769993858 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Dimension Therapeutics (DMTX) traded down $0.03 during mid-day trading on Thursday, hitting $5.95. The company had a trading volume of 27,700 shares, compared to its average volume of 150,214. The company has a current ratio of 2.01, a quick ratio of 3.33 and a debt-to-equity ratio of 0.14. Dimension Therapeutics has a twelve month low of $1.05 and a twelve month high of $6.10.

Dimension Therapeutics (NASDAQ:DMTX) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.20). The firm had revenue of $4.48 million for the quarter. Dimension Therapeutics had a negative net margin of 378.28% and a negative return on equity of 240.95%. sell-side analysts expect that Dimension Therapeutics will post -1.99 earnings per share for the current year.

A number of brokerages have issued reports on DMTX. ValuEngine raised Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 30th. Wells Fargo & Company lowered Dimension Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $9.00 to $6.00 in a research report on Tuesday, October 3rd. Citigroup raised Dimension Therapeutics from a “sell” rating to a “neutral” rating and upped their target price for the company from $5.50 to $6.00 in a research report on Tuesday, October 3rd. Finally, Canaccord Genuity lowered Dimension Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $12.00 to $3.41 in a research report on Wednesday, August 30th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.08.

WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2017/12/14/dimension-therapeutics-dmtx-given-daily-news-sentiment-rating-of-0-16.html.

Dimension Therapeutics Company Profile

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Insider Buying and Selling by Quarter for Dimension Therapeutics (NASDAQ:DMTX)

Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit